Liquid Biopsy

serum+plasma_miRNA_700x233

microRNAs in cancer metastasis: potential for therapy and liquid biopsy

For patients with solid tumors, metastatic disease often represents a turning point in their journey. It remains the most significant hurdle in cancer treatment, accounting for 90% of all deaths resulting from solid tumors (1). Research during the past 20 years has begun to elucidate multiple events that take place during metastatic progression. In the… Read article →


LungCancer+miRNA_700x233

Cancer in the lungs? The blood will tell – miRNA in non-small cell lung cancer

In a previous post, we discussed how small non-coding RNAs could be identified to serve as circulating biomarkers in lung cancer. Now, a new study from Ma et al. defines a promising microRNA signature in peripheral blood mononuclear cells. The signature can distinguish non-small cell lung carcinoma (NSCLC) with 72.62% sensitivity and 82.61% specificity, and squamous… Read article →


Exosomes_700x233

Tumor-derived exosomes

Tumor cells utilize multiple signaling mechanisms to modify surrounding tissue and create a favorable environment for growth and metastasis. Direct cell–cell communication is mediated by gap junctions, which are specialized channels that allow the transfer of ions and small molecules between adjacent cells. Paracrine signaling molecules, such as TGF-beta and fibroblast growth factor, act over a… Read article →



CancerPathwayFinder_700x233

Liquid biopsy: a necessity in the age of personalized medicine

The 2001 introduction of Imatinib (Gleevec) for the treatment of chronic myelogenous leukemia was a watershed moment in cancer therapeutics. In addition to treating a previously fatal leukemia, it opened the door for the further development of targeted therapeutics, molecules designed to specifically inhibit individual oncogenic proteins. The advent of targeted therapy also made the… Read article →